The Coastal Post - February 2000

Experts Find Possible Cure for Alzheimer's

(NUI) - There is good news for people suffering from Alzheimer's disease (AD) and their families. Researchers say a new drug candidate that may slow or halt the progression of AD is in the pipeline.

Axonyx, Inc., (OTC BB: AXYX) began human clinical testing on Phenserine, its lead Alzheimer's disease drug, in December 1999. In preclinical animal studies, Phenserine has shown the ability to inhibit the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. A neurotransmitter is responsible for transferring information from one nerve to another.

Phenserine has also shown potential to reduce the formation of beta amyloid peptide, the toxic product that is found in the brain of patients with Alzheimer's disease and is thought to be associated with nerve cell death.

Earlier this year, studies conducted by Dr. Nigel Grieg and his colleagues at the National Institutes on Aging, suggested that Phenserine is useful in improving cognition and memory.

Alzheimer's is a cruel disease, robbing hundreds of thousands of people the world over of their intellectual capacity and impairs their ability to function both socially and occupationally. That's why Axonyx is working to develop better, more accurate ways of identifying and treating AD and other cognitive disorders.

"The company is looking forward to this opportunity to study the safety and efficacy of this potentially valuable drug for patients afflicted with Alzheimer's disease," Axonyx President Dr. Marvin S. Hausman said.

Coastal Post Home Page